Dysken M W, Kooser J A, Haraszti J S, Davis J M
Arch Gen Psychiatry. 1979 Jul;36(7):789-94. doi: 10.1001/archpsyc.1979.01780070067007.
We report a double-blind, randomized, placebo-controlled study utilizing a within-subjects design on 20 hospitalized, psychiatric patients who participated in sodium amobarbital interviews to determine if the drug has a specific effect in eliciting clinically useful information. The patients selected had difficulty communicating with their primary therapists during the postadmission, diagnostic interviews. Two raters completed a Hamilton Depression Scale, a New Haven Schizophrenia Index, and a Brief Psychiatric Rating Scale after each interview. Although both the amobarbital and saline interviews were moderately useful in obtaining new information, we found no significant difference in the primary therapists' assessments of clinical usefulness. In addition, the drug interview did not uncover material that would aid in the differential diagnosis between depression and schizophrenia. There was, however, a significant negative correlation between the assessment of general usefulness and the time interval between admission and interviewing. We report our only exception, a case of catatonic schizophrenia, in which the patient responded specifically to the drug.
我们报告了一项双盲、随机、安慰剂对照研究，该研究采用受试者内设计，对20名住院精神科患者进行了研究，这些患者参与了异戊巴比妥钠访谈，以确定该药物在引出临床有用信息方面是否具有特定作用。所选患者在入院后的诊断访谈中与他们的主治治疗师沟通存在困难。两名评估者在每次访谈后完成了汉密尔顿抑郁量表、纽黑文精神分裂症指数和简明精神病评定量表。虽然异戊巴比妥钠访谈和生理盐水访谈在获取新信息方面都有一定作用，但我们发现主治治疗师对临床有用性的评估没有显著差异。此外，药物访谈并未揭示有助于区分抑郁症和精神分裂症的材料。然而，总体有用性评估与入院和访谈之间的时间间隔存在显著负相关。我们报告了唯一的例外情况，一名紧张型精神分裂症患者，该患者对药物有特异性反应。
